Pharma companies have had years to hone their arguments justifying sky-high drug prices. You know the speech. Innovation. Value. Breakthroughs. Unmet need. Transformative medicine. Patient access. But someone has to pay the bill. And lately that someone has been the American worker.
The tough news for Big Pharma in 2026 is that its incredible scientific achievements have run into the financial realities of employer-provided healthcare. Millions of patients are being put on GLP-1 drugs. Cancer medications are becoming more effective — and expensive. Specialty drugs, cell and gene therapies keep getting launched. At the same time, employers are staring at healthcare costs that are increasingly out of control. And they’re starting to push back. Last week Disney announced it will no longer cover working spouses who can get insurance through their own employers. The reason? Healthcare costs. Other large employers are grappling with the same dynamics. Here’s your reward, pharma. You invented some great drugs. Now American employers are deciding what benefits they can no longer afford.
Start With a Number: $26,993
That’s the yearly family premium cost for employer-sponsored health insurance in 2025. $26,993. Employees, on average, paid $6,850 of that premium cost. Average premiums for single coverage hit $9,325. That doesn’t take into account all the money you spend when you use your insurance, either.
The average deductible for workers with a general annual deductible was $1,886. Average deductibles climbed to $2,631 for workers at small businesses. One in three covered workers, 34%, had insurance with a deductible of at least $2,000 for single coverage. One in five covered workers with an out-of-pocket maximum had to pay over $6,000 before their insurance kicked in with any real gusto. Welcome to health care in America. First you fork over thousands on insurance. Then you happily fork over thousands more before your insurance does much of anything. Let’s pretend this is “affordable.”
It Gets Better in 2026
Aon estimates that the average employer health-plan cost increased from $16,212 per employee in 2025 to $17,562 in 2026. Employer cost increased 8.8%. Employee payroll premiums increased 6.4%. Employee out-of-pocket spending increased 10.2%. Put premiums and out-of-pocket costs together and the average employee burden reached approximately $5,297 in 2026, up 7.9% in a single year.
Employees aren’t imagining healthcare inflation. They’re experiencing it in their paychecks and at the doctor’s office. And the trajectory isn’t improving.
Business Group on Health’s newest survey projects a median 9.2% increase in employer healthcare costs for 2027 before plan changes, following an estimated 8.5% trend in 2026. It estimates that healthcare costs could rise a cumulative 76% over ten years, including the 2026 and 2027 forecasts.
Eventually, CFOs notice numbers like that. And when CFOs start managing employee healthcare, “comprehensive benefits” quickly becomes “cost optimization.”
Enter the GLP-1 Gold Rush
GLP-1 medications are amazing drugs. They are also something of the ideal pharmaceutical business model. Pick a huge chronic disease. Create a highly effective medication. Broaden the eligible population. Broaden the indications. Push chronic utilization. And let somebody else pay the bill.
For employer plans, that “somebody else” is you. In a recent Business Group on Health survey, nearly 8 in 10 employers reported that GLP-1 drugs were driving up their healthcare costs. Two-thirds covered the medications for weight loss at the time of the survey.
But only 72% of employers who were covering the medications said they were likely to continue doing so in 2027. Employers are already backing away from the drugs. Business Group on Health’s newer 2027 survey showed GLP-1 obesity coverage declining from 72% of employers in 2025 to 60% in 2026.
Apparently, “patient access” sounds wonderful until the invoice reaches the benefits department.
Here’s the Part Pharma Doesn’t Put in the Investor Deck
IQVIA projects U.S. net medicine spending will increase 10.6% in 2025, reaching $606 billion from $548 billion. That’s $58 billion more than we spent last year. GLP-1 drugs added roughly $14 billion of that growth figure ($9.6 billion from therapies approved for weight loss and associated conditions).
Commercial insurer patient pharmacy deductibles and co-pays grew 5% in 2025 and were 37% higher than they were five years ago. There’s your innovation paradox. Pharma churns out better drugs. Spending soars. Payers restrict access. Patients pay higher out-of-pocket costs. And we pat ourselves on the back for ‘making healthcare better’.
Pharmacy Is Eating the Healthcare Budget
Prescription drugs aren’t just another cost center for employers. They are rapidly becoming one of the largest expenses for employers that offer health insurance to their employees. Pharmacy made up 25% of total employer healthcare expenditures, according to Business Group on Health. That’s right, one out of every four healthcare dollars went toward drugs, and it was expected to rise another 12% in 2026.
Employers aren’t simply purchasing doctor visits and hospital stays. They are subsidizing one of the most profitable pharmaceutical industries in the world. And employers can’t print money like the federal government. Something’s gotta give.
Then There’s Cancer
If GLP-1s are the high-volume budget buster, oncology drugs are the high-cost clinical conundrum. Cancer is eating employers’ healthcare budgets. Not just sometimes.
For the past five years running. In Business Group on Health’s latest annual survey, 70% of employers said cancer was their top healthcare cost driver in 2026, compared with 58% in 2025. A whopping 92% of employers said cancer was one of their top three cost drivers.
IQVIA recently reported that “‘protected’ branded drugs,” which usually refers to oncology drugs and immunology products, were the main drivers of the substantial increase in U.S. drug spending in 2025. And now we get to the ethically awkward part. What do you tell an employee facing metastatic cancer? That their newest treatment option is too expensive? How about the employee’s spouse? Kids? Please. Like most expensive medical scenarios, employers just pick up the tab. And since health plans don’t have unlimited funds, that money has to come from somewhere. Enter the rest of your workforce.
Congratulations. You’re Helping Pay for Someone Else’s $200,000 Drug.
This is the part nobody wants to talk about. Most employees will never use a $200,000 oncology medication. Most will never qualify for gene therapy. Many will never be on a GLP-1. Doesn’t matter. You’re still footing the bill. Directly through premiums. Out of pocket through deductibles. Out of pocket through coinsurance. Out of pocket through higher out-of-pocket maximums. Out of pocket through tighter formularies. And time wasted through prior authorization. You may even pay out of pocket when your spouse is kicked off of your company plan because they “technically have coverage” elsewhere. And yes, you may pay through compensation. Employer-provided healthcare is compensation. Every dollar above the previous year that an employer spends on healthcare has to compete with wages, bonuses, new hiring, retirement matching, and every other benefit. The pharmaceutical industry doesn’t send you that bill. Your employer does.
Pharma Loves Talking About “Value”
Ok this is my favorite one. “This drug adds value to the healthcare system.” Ok it may. A GLP-1 may help prevent diabetes, CV events, sleep apnea, and other expensive downstream complications. A cancer drug may add years to life. That is real value. But there’s a problem. Money. Value does not equal affordable. Sure, a Ferrari is worth $300k. Doesn’t mean I can afford it. Pharma loves pricing drugs based on theoretical value. Employers work on annual budgets. Try explaining this to a CFO. “Hey, it’s ok if you spend $15 million more on GLP-1s this year. You’ll save on CV events in 2041.” I can guarantee you that will go over very well. Half your employees will be working elsewhere by then.
The Most Absurd Part: We Built an Entire Industry Between Pharma and the Employer
Oh wait, it’s not just drug companies that are screwing us. We made the PBMs too. Because heaven forbid we should just be able to buy drugs without an advanced degree in Price Canyon. Now employers have to deal with: List prices. Rebates. Administrative fees. Formulary payments. Specialty pharmacy margins. Spread pricing. Rebate guarantees. Prior authorization. Step therapy. Manufacturer “patient” assistance programs. Contracts so Byzantine they require consultants to interpret to the folks who negotiated said contracts. The drug company tells you the PBM is gouging you. The PBM tells you the manufacturer is price gouging. The Insurer cries high utilization. The Hospital cries low reimbursement. Blame seems to abound for everyone. Miraculously, everyone also appears to be getting paid. Except for the one person who actually needs the drug. The employee is forced to pay a $2,000 deductible.
The Great American Healthcare Shell Game
Here’s how it works. Pharma ramps up spending. PBMs renegotiate. Insurers shift prices. Hospitals consolidate. Employers absorb it. Until they can’t. Suddenly it shifts. The premium rises. Maybe. The deductible rises. Maybe. The formulary narrows. Maybe you need pre-authorization for your GLP-1 now. Maybe your specialty drug is mailed from a different pharmacy. Maybe your spouse is ineligible anymore. Maybe your company switches networks entirely. No one ever “cut healthcare”. They “optimized the benefit design.” Corporate America is filled with euphemisms for “we’re making you pay more”.
And Now the CFO Has Entered the Room
This may be THE most important trend of all. Almost 8 out of 10 employers say exec leadership is involved in GLP-1 coverage decisions, according to Business Group on Health’s 2026 GLP-1 survey. You should care about that. It’s no longer just medical directors and benefits executives deciding if your drug gets covered. People who are responsible for corporate financial performance are paying attention. And they will ask questions that are considerably less romantic than the ones pharma is used to answering. They will not ask: “How innovative is the mechanism of action?” They will ask: How many employees are eligible? What’s the net cost? How fast is utilization growing? How long do patients stay on therapy? Where are the medical savings? When do we see those savings? How much of those savings do we capture before the employee leaves the company? And eventually: Why the hell are we paying this much?
The Numbers Are Becoming Impossible to Ignore
Put the numbers next to each other:
- $26,993: average employer-sponsored family premium in 2025.
- $6,850: average employee contribution toward family coverage.
- $1,886: average single deductible among workers in plans with a deductible.
- $5,297: Aon’s estimated average employee premium-plus-out-of-pocket burden in 2026.
- $606 billion: U.S. net medicine spending in 2025.
- $14 billion: 2025 spending growth attributable to GIP/GLP-1 medicines.
- 25%: employer healthcare spending now attributable to pharmacy.
- 12%: estimated employer pharmacy-cost increase in 2026.
- 70%: employers identifying cancer as their No. 1 healthcare cost driver in 2026.
- 60%: employers covering GLP-1s for obesity in 2026, down from 72% in 2025.
- 9.2%: projected employer healthcare cost trend for 2027 before plan changes.
This isn’t sustainable mathematics. It’s a transfer mechanism. Money moves from employers and employees into an extraordinarily expensive healthcare ecosystem. And when employers finally say “enough,” the healthcare industry doesn’t absorb the pain. Employees do.
Thank You, Pharma
Thanks, pharma. Really. Thanks for developing drugs that can make patients lose 20% of their body weight. Thanks for cancer drugs that can buy patients extra months or years with their loved ones. Thanks for being able to treat diseases that doctors didn’t know how to treat just one generation ago. I’m impressed by the science stuff. But please stop patting yourselves on the back for “patient access” while you build pricing models that make access impossible to pay for.
Drug access doesn’t happen when it’s approved by the FDA. Access happens when someone can actually afford to purchase it.
And increasingly, that someone is not an employer. So they’re doing what any logical company does when a cost outpaces every other expense: They’re trimming. Constraining. Shifting costs. Switching vendors. Restricting eligibility. Adding authorization requirements. Cutting coverage. And making their employees pay more.
Pharma companies may not be directly raising your health insurance deductible, but they don’t need to. Drug companies simply raise the price of the system that sets your deductible. That’s the bit they leave out of the beautiful photos of smiling patients playing in meadows and chasing grandchildren. They should probably include one more frame at the end. The employee sitting at their kitchen table staring at next year’s benefits packet. Higher premium. Higher deductible. New formulary. Increased prior authorization. Pay-more-if-you’re-married penalty. And maybe no coverage of the drug their doctor prescribed.
Fade to black: Ask your employer if you can afford our innovations. Because that, my friends, is where we’re headed. If we don’t fix it. We have engineered a drug innovation wonderland where medicine is made that our grandparents would have thought miraculous. We just haven’t engineered a way to pay for it all. And until pharmaceutical companies, PBMs, insurers, hospitals, and legislators care about that consequence, employers will continue to “solve” the problem by making employees pay part of the bill. So thank you for the drugs, pharma. They are truly amazing. Too bad we’re working hard at making the health insurance we need to pay for them unaffordable.
Drug companies have made amazing innovations that allow us to live longer, healthier lives. They should be celebrated for the drugs that treat cancer. Diabetes. Heart disease. Infectious diseases. So many things. But there comes a point when innovating and trying to squeeze every last dime become two very different priorities.
When pharma profiteering through higher and higher margins, aggressive pricing tactics, patent extension strategies, and blockbuster drug revenues causes American employers to scale back benefits, force workers to pay more premiums and higher deductibles, and price patients out of their own medicines, we have a problem.
Perhaps the greatest challenge in confronting elevated drug prices is the narrative employees of pharma companies tell themselves: “research and development costs are too high,” “insurance companies and PBMs are the true villains,” “patients never pay the sticker price anyway,” “we need high margins to invest in future discoveries,” or “the market sets the price.” While each of these statements holds some validity, they can also serve as a defense mechanism to avoid facing an inconvenient truth:
Pharma companies consciously decide how much to charge for their drugs and how fiercely they will defend those profits. PBMs, insurers, hospitals, and government policy are all definitely at fault for America’s broken healthcare system, but blaming others does not absolve drug makers of blame. When an industry whose purpose is to better humanity starts justifying prices that price patients out of treatment, pharma employees should feel empowered to question the status quo instead of echoing it.
Yes, companies need to turn a profit in order to fund new discoveries and reward risk. But if putting shareholders first starts harming patients’ access to healthcare, it’s fair for society to question if the system works for patients. Or if patients are working for the system.
